Food and Drug Administration Commissioner Dr. Marty Makary resigned on May 12 after weeks of mounting pressure from within the Trump administration. His departure marks the latest shakeup in federal health agencies under Health and Human Services Secretary Robert F. Kennedy Jr.
According to multiple reports, Makary faced intense pressure over his resistance to approving the sale of fruit-flavored e-cigarettes, an issue that prompted President Trump to confront him directly. The Wall Street Journal reported that Trump saw vape flavor approval as important to his political base. Makary had also clashed with White House and HHS officials over a range of policy matters, creating what insiders described as constant chaos and internal conflict at the agency.
President Trump acknowledged the leadership change as he prepared to depart for his trip to Beijing, saying Makary is a wonderful man and that a deputy would take over temporarily. The administration has not yet named a permanent replacement, though analysts expect the next commissioner will be a more conventional pick aligned with the MAHA agenda.
The resignation comes at a critical time for the FDA, which is dealing with the hantavirus cruise ship outbreak response, ongoing drug approval decisions, and debates over abortion pill access. Health policy experts warn that continued leadership turnover at federal health agencies undermines public trust and institutional capacity during a period of multiple health crises.
Public Citizen's health research director Robert Steinbrook described the ouster as part of a broader pattern of public health chaos under the current administration, noting that systematic dismantling of federal health agencies has accelerated in recent months.